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Protein kinase C is stereospecifically ctivated by sn-1,2-(S)-diglycerides. A second chiral center was introduced into the diglycerides by preparing 
the 3-methyl derivatives. The activation of protein kinase C was also stereospecific with respect to the new chiral center established at the C3 position 
of the methylated diglycerides. The stereospecificity of protein kinase C directed towards the C2 and C3 positions of the diglycerides is matched 
in the analogous C29 and C30 stereocenters of the tumor promoting debromoaplysiatoxins. Thi  finding strengthens the view that the structurally 
diverse tumor promotors contain the embedded diglyceride-like pharmacophore. 
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1. INTRODUCTION 
Protein kinase C (PKC) serves as an important con- 
trol element in cellular function [1]. The enzyme is tran- 
siently and physiologically activated by diglycerides, 
which are generated by hydrolysis of endogenous 
polyphosphoinositides by a temporally regulated phos- 
pholipase C [1,2]. Liberated diglycerides bind to the 
regulatory domain of PKC and cause its activation, 
allowing the enzyme to phosphorylate its natural 
substrates at serine or threonine residues [3]. PKC is 
deactivated by the metabolism of the effector diglyceri- 
des by diglyceride kinase or diglyceride lipase [1,4]. 
The nature of the diglyceride binding-site has been 
probed with a substantial number of diglycerides. The 
interaction is stereospecific, with only the naturally oc- 
curring sn-l,2-(S)-enantiomer being active, both in 
vitro and in vivo [5-7]. Studies on the structure/activity 
relationship have demonstrated great specificity of in- 
teraction with respect to diglycerides. For example, 
1,3-diglycerides are inactive, and the addition of a 
single methyl group at the sn-1 position of an otherwise 
active diglyceride almost completely abolishes activity 
[8,9]. PKC's great specificity with respect to digly- 
cerides must be contrasted, however, to its apparent 
lack of specificity with regard to the structurally diverse 
tumor promoters [10]. The tumor promoters capable of 
potently activating PKC include phorbol esters, in- 
genols, teleocidins, and aplysiatoxins [1,11-13]. These 
molecules function in vivo by activating PKC per- 
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manently on a physiological time scale, since they are 
not readily metabolized and are tightly bound to the en- 
zyme [14-16]. 
An important issue to resolve is how the same effec- 
tor binding-site in PKC can specifcally recognize both 
the diglycerides and the apparently structurally dissimi- 
lar tumor promoters. Recently, we have presented a
stereochemical model which addresses this issue and ex- 
plains how the structurally diverse tumor promoters 
and the diglycerides can all be accommodated by the 
same binding-site [I0]. Debromoaplysiatoxin (DAT; 1) 
and 3-deoxydebromoaplysiatoxin playa central role in 
this model [10]. The aplysiatoxins provide synthetically 
manipulable templates which are crucial in the develop- 
ment of the structural hypothesis. The model draws at- 
tention to the structural correlation between DAT and 
its cognate sn-l,2-diglyceride 2, as shown in Fig. 1. Of 
considerable interest is the C30 stereochemistry of 
DAT. It would be predicted that this stereochemical 
preference should carry over to diglycerides if our 
model is cogent. In this communication, it is demon- 
strated that the binding of 3-methyldiglycerides to PKC 
and the subsequent activation of PKC are stereospecific 
with respect to both the C2 position and the C3 position 
of the diglycerides. Furthermore, the absolute stereo- 
chemical preference is exactly as predicted by our 
model. This study thus establishes the stereochemistry 
of PKC activator binding and, in addition, strongly 
supports out model. 
2. MATERIALS AND METHODS 
2.1. PKC purification and enzyme assays 
PKC was partially purified from rat brain as previously described 
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Fig. 1. Proposed PKC activation model. Identical symbols indicate quivalent atoms. 
[6]. PKC activity was assayed by measuring the incorporation of 32p 
from [3,-32p]ATP into lysine-rich histone type VS, essentially as 
reported [6], with the following modifications: for incorporation i to 
the assay, mixtures of PS and diglycerides in chloroform were dried 
down under nitrogen for 30 min and resuspended in 60 mM Tris-HCl 
pH 7.5, 3 mM EDTA by sonication for 2 min with a Kontes micro- 
ultrasonic ell disrupter. Incubations were carried out at 30°C for 5 
min. 
2.2. Synthesis of analogs 
The diglyceride analogs 6 -9  were synthesized as summarized in 
Scheme 1. Addition of methylmagnesium bromide on D-glyceral- 
dehyde acetonide, i.e. step a.1, yielded a ca 3:1 mixture of the two ex- 
pected diastereomers, which were separated by silica gel chromato- 
graphy after introduction of the two acyl groups. In order to assign 
the stereochemistry of these diastereomers, the stereochemically- 
defined synthesis of the intermediate 4 (X = C6HsCH2), starting from 
diethyl L-( + )-tartrate, was carried out as outlined in Scheme 2. Com- 
parison of their spectroscopic data (IH and 13C NMR, MS, IR, and 
aD) established unambiguously that the minor diastereomer 4 obtain- 
ed in the first synthesis i the antipode of the threo diastereomer 12. 
The four diglyceride analogs 4 -7  thus synthesized gave satisfac- 
tory spectroscopic data, including the following: 6: [aID + 7.5 ° (C 1.5, 
CH2C12); IH NMR (500 MHz, CDCI3) t5 4.97 (1H, dt, J = 4.3, 6.7 Hz), 
4.40 (1H, dd, J=4.2, 11.9 Hz), 4.12 (IH, dd, J=6.7, 11.9 Hz), 3.94 
(1H, br), 2.36 (2H, t, J =7.6 Hz), 1.29 (2H, t, J =7.5 Hz), 1.62 (4H, 
m), 1.30 (8H, m), 1.21 (3H, d, J=6.5 Hz), and 0.89 (6H, m). 7: [aID 
--20.7 ° (C 2.1, CH2C12); 1H NMR (500 MHz, CDCI3) t5 4.94 (1 H, dt, 
J =4.7, 5.5 Hz), 4.32 (2H, d, J =4.7 Hz), 3.90 (1H, m), 2.34 (2H, t, 
6.5 Hz), 2.31 (2H, t, J=7.7 Hz), 1.64 (4H, m), 1.31 (8H, m), 1.22 
(3H, d, J = 4.4 Hz), and 0.90 (6H, m). 8: [c~]D + 1.6 ° (c 0.43, CH2C12; 
IH NMR (500 MHz, CDCI3) t5 5.24 (4H, m), 4.87 (1H, dt, J = 4.3, 6.6 
Hz), 4.30 (1H, dd, J=4.3, 11.9 Hz), 4.02 (1H, dd, J=6.7, 11.9 Hz), 
3.85 (1H, dt, J =4.3, 6.4 Hz), 2.26 (1H, t, J=7.5 Hz), 2.19 (IH, t, 
J=7.6 Hz), and 1.11 (3H, d, J=6.5 Hz). 9: [CdD -11.0 ° (c 1.2, 
CH2C12); IH NMR (500 MHz, CDCI3) t5 5.34 (4H, m), 4.94 (1H, dt, 
J=4.8,  9.9 Hz), 4.32 (2H, d, J=4.6 Hz), 3.90 (1H, dq, J=5.7 Hz), 
2.34 (2H, t, J=7.5 Hz), 2.31 (2H, t, J=7.7 Hz), and 1.22 (3H, d, 
J = 6.4 Hz). 
2.3. Materials 
Bovine phosphatidylserine (PS) was obtained from Avanti Polar 
Me 
Me 
OHC.,~.//O 
OCOR OCOR 
= 
Me"-.vi"~v/OCOR b Me"'....,,""'5'vOCOR 
= 
OX QH 
6 : RCO=n-hexanoyl 
8 : RCO=oleoyl 
OCOR OCOR 
b Me~OCOR Me,..~,,,,.,...,,,/OCOR 
OX OH 
5 7 : RCO=n-hexanoyl 
9 : RCO=oleoyl 
Scheme 1. Synthesis of 3-methylglycerides. Reagents for the dihexanoyl series: a. 1. MeMgBr/THF, 2. C6HsCH2Br/KH/imidazole/THF-DMF, 
3. AcOH/MeOH, 4. n-hexanoyl chloride/py, followed by silica gel chromatography separation, b. 1. H2/Pd(OH)2 on C/MeOH. 
Reagents for the dioleoyl series: a. 1. same as above. 2. p-MeOC6H4CH2Br/NaH/THF-DMF, 3. same as above, 4. oleoyl chloride/py, followed 
by silica gel chromatography separation, b. 1. DDQ/CH2C12. 
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Scheme 2. Stereochemically-defined synthesis of 3-methylated sn-l,2-diglycerides. Reagents: a. 1. C6HsCH(OMe)2/p-TsOH. py/ C6H6, 2. 
NaBHjEtOH, 3. DIBAL/CH2CI2, 4. MeC(OMe)2Me/p-TsOH • py/THF, b. 1. p-TsC1/py, 2. LAH/THF, 3. AcOH/MeOH, 4. n-hexanoyl 
chloride/py. 
Lipids (Birmingham, AL). 1,2-Dioleoyl-sn-glycerol and histone type 
VS were from Sigma. Protease inhibitors were products of Boehr- 
inger. [7-3zP]ATP (-3000 Ci/mmol) was from Amersham. 
3. RESULTS 
Rat brain PKC, partially purified as described in sec- 
tion 2, was found to have the same properties as the ful- 
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Fig. 2. Activation of PKC by diolein and 3-methyldiglyceride analogs. 
(A) Activation of PKC by diolein. (B) Activation of PKC by the 
3-methyldiglyceride analogs 8 (-) and 9 (% inset). Results are average 
values of a typical experiment done in triplicate _+ the standard evia- 
tion from the mean. 
ly purified Ca2+-phospholipid ependent protein 
kinase C [6,17]. With the rat brain preparation, 
sn-l,2-diolein bound to and activated PKC with a 
Kd=0.09 #M and a Vmax=9.36 nmol/min/mg (Fig. 
2A). The two diastereomeric 3-methyldiglyceride ana- 
logs 8 and 9 were prepared and studied as PKC ac- 
tivators (Fig. 2B). As can be seen here, only analog 8 
was active. This compound bound to PKC approx- 
imately two-fold less well than (S)-diolein 2 (Kd = 0.20; 
Vmax=7.70 nmol/min/mg). The second methylated 
diastereomer 9 was basically inactive and elicited ap- 
proximately 2°7o of the activity of the active 3-methyl 
analog 8. This amount of activity is not considered to be 
significant, since only a 2°7o contamination of 8 would 
result in the observed activation, and possible con- 
tamination at this level would not have been detected by 
the analytical methods employed. The presence of a 
small contamination from 8 is probably the reason why 
saturation conditions could not be reached with the 
high concentrations (up to 20 #M) of 9 used (Fig. 2B, in- 
set). The PKC activation observed when the different 
3-methyldiglyceride analogs (6-9) were used at a con- 
centration of 5/zM is shown in Fig. 3. The nature of the 
fatty acid groups of the diglyceride did not affect the 
observed stereospecificity, as can be seen with the 
dihexanoyl analogs (6 and 7). 
4. DISCUSSION 
The experiments reported here probed the nature of 
the diglyceride binding-site of PKC. The stereochemical 
requirement at the sn-2 position had already been 
demonstrated [6]. Although diglycerides do not possess 
a second chiral center, proposed tumor promoting 
diglyceride surrogates do. For example, compared with 
diglycerides, the proposed pharmacophore of DAT 
contains one additional chiral center at the C30 position 
(Fig. 1). It was thus important to probe the stereochem- 
ical requirement in the synthetic 3-methyldiglyceride 
series, to determine if it matches that found in the 
aplysiatoxin series. If this turned out to be the case, it 
would further strengthen the structural link forged bet- 
ween diglycerides and aplysiatoxins [10]. In this connec- 
tion, it is interesting to note that methylated iglycer- 
ides 6 and 7 were studied previously, but their behavior 
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Fig. 3. Effect of diacylglycerol analogs as PKC activators. PKC was 
assayed as described in section 2 in the presence of PS and 2 mol% (5 
#M) diolein (DO) or 3-methyldiglyceride analogs. Results are the 
average of triplicate xperiments _+ the standard eviation from the 
mean. 
towards PKC appeared to be inconsistent with our 
hypothesis [10]. For this reason, we have independently 
synthesized methylated diglycerides 6 and 7, established 
their stereochemistry unambiguously, and proved their 
biological behaviors to be consistent with our hypothe- 
sis. Furthermore, the corresponding diolein analogs 8 
and 9 exhibit biological behavior parallel to that of 6 
and 7, demonstrating that the stereochemical require- 
ment at the second asymmetric center of diglycerides i  
identical with that of aplysiatoxins. This finding lends 
strong support o the structural hypothesis that we have 
proposed which links structural elements of the 
diglycerides to the pharmacophore of the tumor pro- 
moters [10]. 
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